Increasing prevalence of anxiety and depression, coupled with innovation in pharmaceutical treatments and growing demand for mental health solutions, fuels growth in the anxiety disorders and ...
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...
He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized ... and neurological disorders, having contributed to the successful ...
We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...